Physician profile
Michael R Davis
NPI 1669429171
$12,167.51
in general payments reported to CMS, 2019-2025
43 companies · $1,253 in 2025
The $1,253 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,578 · 2020: $1,789 · 2021: $1,987 · 2022: $1,994 · 2023: $1,847 · 2024: $1,718 · 2025: $1,253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,794 · Education: $24.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,794.26 |
| Education | $24.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,278.79 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $1,869.72 | 2019-2025 | Mounjaro, Jardiance |
| Abbott Laboratories | $901.31 | 2020-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $845.18 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $791.48 | 2019-2023 | |
| Medtronic, INC. | $720.44 | 2021-2025 | Minimed 780g, Inpen Smart Insulin Delivery System, Minimed 770g |
| Bayer Healthcare Pharmaceuticals INC. | $626.95 | 2021-2025 | |
| Amgen INC. | $438.84 | 2019-2025 | Tepezza, Evenity, Repatha |
| Amarin Pharma, INC. | $379.44 | 2019-2022 | |
| Corcept Therapeutics | $342.02 | 2020-2025 | Korlym |
| Becton, Dickinson and Company | $227.47 | 2019-2022 | |
| Abbvie INC. | $219.69 | 2021-2025 | Synthroid |
| Xeris Pharmaceuticals, INC. | $185.37 | 2020-2025 | Gvoke Hypopen |
| Dexcom, INC. | $174.87 | 2021-2023 | Dexcom G6 Transmitter |
| Horizon Therapeutics Plc | $173.96 | 2020-2023 | Tepezza |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $146.36 | 2024 | Kcentra |
| Medtronic Minimed, INC. | $140.11 | 2019-2020 | |
| Mannkind Corporation | $124.64 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.83 | 2019-2025 | Jardiance |
| Tandem Diabetes Care, INC. | $120.04 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amneal Pharmaceuticals LLC | $115.80 | 2022-2024 | Unithroid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.52 | 2021-2024 | Xifaxan, Trulance |
| Rochester Medical Corporation | $101.44 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $99.13 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $94.53 | 2023-2025 | |
| Esperion Therapeutics, INC. | $91.84 | 2020-2022 | |
| Chiesi USA, INC. | $91.37 | 2024-2025 | Mycapssa |
| Insulet Corporation | $89.33 | 2019-2023 | Omnipod |
| Radius Health, INC. | $77.49 | 2020-2025 | Tymlos |
| Janssen Pharmaceuticals, INC | $67.67 | 2019-2020 | |
| Beta Bionics, INC. | $62.80 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Eisai INC. | $55.70 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $45.22 | 2025 | |
| Merck Sharp & Dohme LLC | $44.32 | 2019-2023 | Dificid |
| Recordati_rare_diseases_inc. | $40.75 | 2023-2025 | Isturisa, Signifor Lar |
| Pfizer INC. | $31.36 | 2022-2024 | |
| Zealand Pharma US, INC. | $23.40 | 2021 | |
| Amryt Pharma Holdings LTD | $20.93 | 2022 | |
| Antares Pharma, INC. | $19.95 | 2021 | |
| Ascendis Pharma Endocrinology INC | $16.20 | 2024 | |
| Genmab U.S., INC. | $15.29 | 2024 | Epkinly |
| Arbor Pharmaceuticals, INC. | $14.58 | 2021 | |
| Shire North American Group INC | $13.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.